FGF2 and central nervous system cancer: Blocking FGF2 signaling with the FGFR inhibitor AZD4547, which is evaluated in clinical trials as anticancer drugs [34], abolished YAP-conferred radioresistance and subsequent malignant progression of gliomas both in vitro and in vivo.